Download PDF
1 / Pages

Other users also viewed these articles

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the ¿no evidence of disease activity¿ parameter A. Pato Pato; E. Costa Arpín; A. Rodríguez Regal; I. Rodríguez Constenla; I. Cimas Hernando; I. Muñoz Pousa; L. Naya Ríos; J.R. Lorenzo González; M.C. Amigo Jorrín; J.M. Prieto González;
Neurologia. 2021;36:346-52
Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus D.A. García Estévez; I. Pinal Osorio; A. Pato Pato;
10.1016/j.nrleng.2024.02.006